10-QPeriod: Q3 FY2011

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 2011

Filed November 8, 2011For Securities:MRK

Summary

Merck & Co., Inc. reported strong financial performance for the third quarter and first nine months of 2011, showcasing significant year-over-year improvements in net income and earnings per share. Revenue growth was driven by key pharmaceutical products like Januvia, Janumet, and Singulair, alongside robust performance in the Animal Health segment. The company also saw a positive impact from foreign exchange rates. Despite ongoing restructuring costs related to the Merck-Schering-Plough integration, which are expected to yield substantial future savings, the company demonstrated solid operational execution. Merck continues to navigate a complex regulatory and competitive landscape, including ongoing litigation and patent expiries for some established products. However, strategic initiatives such as the acquisition of Inspire Pharmaceuticals and pipeline advancements, including regulatory filings and approvals for new indications, position the company for continued growth. The company's financial health is further supported by strong operating cash flows and a disciplined approach to capital allocation, including share repurchases and dividend payments.

Financial Highlights

50 data points
Beta

Revenue

$12.02B

63.8% Gross Margin

Net Income

$1.69B

14.1% Net Margin

EPS (Diluted)

$0.55

Total Assets

$106.53B

Cash & Equivalents

$14.25B

Free Cash Flow

$4.58B

Financial Statements
Beta
Revenue$12.02B
Cost of Revenue$4.35B
Gross Profit$7.67B
R&D Expenses$1.95B
SG&A Expenses$3.34B
Interest Expense$176.00M
Net Income$1.69B
EPS (Basic)$0.55
EPS (Diluted)$0.55
Shares Outstanding (Basic)3.07B
Shares Outstanding (Diluted)3.09B

Key Highlights

  • 1Net income attributable to Merck & Co., Inc. increased substantially to $1.69 billion for Q3 2011 ($0.55 EPS) and $4.76 billion for the first nine months ($1.53 EPS), representing significant improvements over the prior year periods.
  • 2Worldwide sales grew 8% in Q3 2011 to $12.0 billion and 5% for the nine-month period to $35.8 billion, driven by strong performance in pharmaceuticals (Januvia, Janumet, Singulair) and Animal Health.
  • 3The company is actively managing restructuring costs associated with the merger integration, with anticipated annual savings of $4.0 billion to $4.6 billion upon completion.
  • 4Merck completed the acquisition of Inspire Pharmaceuticals for approximately $420 million in May 2011, expanding its ophthalmic product portfolio.
  • 5Key products like Januvia and Janumet showed robust growth, with Januvia sales up 41% in Q3 and Janumet sales up 42%.
  • 6The company continues to advance its R&D pipeline, with recent approvals and submissions, including for Juvisync and Zoely, and progress in Phase III trials for several promising candidates.
  • 7Merck maintained a strong liquidity position with $18.0 billion in cash and investments at September 30, 2011, and generated $9.2 billion in cash from operating activities for the first nine months.

Frequently Asked Questions

Sales growth was primarily driven by higher sales of key pharmaceutical products such as Januvia, Janumet, Singulair, Gardasil, Zostavax, RotaTeq, and Isentress. Additionally, the Animal Health segment showed increased sales. Favorable foreign exchange rates also contributed positively to the global sales performance.

Merck is executing a Merger Restructuring Program to optimize its cost structure following the integration of Merck and Schering-Plough businesses. This program, along with the 2008 Restructuring Program, is expected to yield significant annual savings, estimated between $4.0 billion to $4.6 billion upon completion. These programs involve workforce reductions and facility consolidations, with associated restructuring costs recorded in the period.

The report details significant ongoing legal proceedings, including various litigations related to Vioxx (product liability, shareholder, and foreign lawsuits), Fosamax (product liability for jaw injuries and femur fractures), NuvaRing (product liability), Propecia/Proscar (alleged persistent sexual side effects), and Vytorin/Zetia (securities and ERISA litigation). The company also faces investigations related to marketing practices and patent litigations for several key products. While Merck believes it has meritorious defenses, unfavorable outcomes could materially impact financial position and results of operations.

Merck acquired Inspire Pharmaceuticals for approximately $420 million in May 2011. This transaction was accounted for as a business acquisition, with assets and liabilities recorded at fair value. The acquisition is expected to expand Merck's ophthalmic product portfolio. The financial impact of Inspire's historical results was not considered significant enough to warrant pro forma financial information.